

# PathHunter® eXpress GLP1R CHO-K1 β-Arrestin GPCR Assay

Catalog Number: 93-0300E2 Lot Number: See Vial

Contents: 1 x 10<sup>6</sup> cells per vial in 0.1 mL

## **Background**

PathHunter eXpress  $\beta$ -Arrestin GPCR cells are engineered to co-express the ProLink<sup>TM</sup> (PK) tagged GPCR and the Enzyme Acceptor (EA) tagged  $\beta$ -Arrestin. Activation of the GPCR-PK induces  $\beta$ -Arrestin-EA recruitment, forcing complementation of the two  $\beta$ -galactosidase enzyme fragments (EA and PK). The resulting functional enzyme hydrolyzes substrate to generate a chemiluminescent signal. These cells have been modified to prevent long term propagation and expansion using a proprietary compound that has no apparent effect on assay performance.

#### **Product Information**

Target GPCR: GLP1R

**Description:** Glucagon-like peptide receptor 1

Receptor Family: Glucagon

Coupling: Gs

Accession Number: NM\_002062.3

GPCR Species: Human

**β-Arrestin Isoform:**  $\beta$ -Arrestin-2

ProLink™ Tag: PK1


Cell Type: CHO-K1

**Storage:** Short term (<24 h): Store at -80°C; Long term (>24 h): Store in vapor phase of liquid nitrogen.

#### **Functional Performance**

Cells were plated in a 96-well plate and stimulated with a control agonist, using the assay conditions described below. Following stimulation, signal was detected according to the recommended protocol. Please refer below for information on control compounds.

Cell Number/Well:



Control Agonist:	Exendin-4
Cell Plating Reagent:	AssayComplete™ Cell Plating 0 Reagent
Cell Incubation Time (Hours):	48
Agonist Incubation Time (Min	utes): 90
Agonist Incubation Temperate	ure (°C): 37
EC <sub>50</sub> for Agonist Stimulation (	n <b>M):</b> 2.4
Signal:Background at Agonis	t E <sub>max</sub> : 12.9

Important! This assay requires an additional step: Please refer to Additional Protocol Information section.

10000



# **Additional Ligand Information**

Control Agonist: Exendin-4

**Vendor:** Eurofins DiscoverX<sup>®</sup> (Catalog No. 92-1115)

### **Additional Protocol Information**

**Additional Protocol Notes:** It is recommended that the control compound be serially diluted in a base media (or buffer) + 1% FBS to ensure optimal assay performance.

# **Limited Use License Agreement**

These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License.

Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.

Ordering: +1.510.979.1415 option 4 or e-mail CustomerServiceDRX@eurofins.com
Technical support: +1.510.979.1415 option 5 or e-mail DRX\_SupportUS@eurofinsUS.com

General product information: www.discoverx.com

Generated on: October 29, 2020